Cibus, Inc. Class A (CBUS)

Over the past six months, Cibus's stock has been impacted by several events. A restructuring and workforce reduction in July 2025, focusing on near-term commercial opportunities, led to a stock decline. The FDA review completion for gene-edited alfalfa in June 2025 resulted in a stock gain. The Q3 2025 earnings report in November 2025, with missed EPS forecasts, caused a stock decline, although the stock drifted higher in the following weeks. A strategic realignment in October 2024 included cost reduction initiatives. The share price saw fluctuations in late 2025 and early 2026.

The agricultural industry is highly seasonal, influencing the sale of plant and seed products. This seasonality leads to fluctuations in Cibus's quarterly sales and profitability. Climate change and extreme weather events could impact the quality, volume, and cost of seeds, affecting Cibus's royalty payments.

Cibus, Inc. is an agricultural technology company specializing in gene-edited plant traits, licensing them to seed companies for royalties. The company focuses on enhancing farming productivity and creating renewable, low-carbon plant products through its Rapid Trait Development System (RTDS®). Cibus develops productivity traits for higher yields and reduced reliance on chemicals and fertilizers, sustainable ingredients to replace fossil fuel-based ones, and biofragrance products. Key products include productivity traits addressing weeds and diseases in crops like canola, rice, soybean, corn, and wheat, weed management traits like HT1 and HT3 for rice, customer-funded programs in crop-based sustainable ingredients, bio-based fermentation fragrance products, and Pod Shatter Reduction (PSR) for canola and winter oilseed rape.

Cibus, Inc. is headquartered in San Diego, California. The company has expanded into Asia through a partnership with AgVaya to develop commercial relationships in India. Commercial launches for rice herbicide tolerance traits are scheduled for Latin America in 2027, the U.S. in 2028, and Asia closer to 2030.

Cibus's brand reputation has been affected by several events. The company has a news sentiment score of 0.43, which is lower than the average. Strategic restructuring and workforce reduction had a negative impact. Positive regulatory development with the FDA review completion for gene-edited alfalfa had a positive impact. Missing EPS forecasts in Q3 2025 could have a short-term negative impact.

Cibus, Inc. has a diverse ownership structure. Retail investors hold the largest share at 43%. Individual insiders own 30.4% of the shares, with Rory Riggs being the largest individual shareholder. Institutional investors hold 26.6% of the shares, with major holders including Fmr Llc and Vanguard Group Inc. The top 5 shareholders control approximately 51% of the company.